Sakata K - Search Results

1

High-dose-rate versus low-dose-rate intracavitary therapy for carcinoma of the uterine cervix: a randomized trial.

Hareyama M, Sakata K, Oouchi A, Nagakura H, Shido M, Someya M, Koito K. Hareyama M, et al. Among authors: sakata k. Cancer. 2002 Jan 1;94(1):117-24. doi: 10.1002/cncr.10207. Cancer. 2002. PMID: 11815967 Free article. Clinical Trial.

2

Results of external irradiation and low-dose-rate intraluminal brachytherapy for esophageal cancer.

Someya M, Sakata K, Saito A, Nagakura H, Oouchi A, Hareyama M. Someya M, et al. Among authors: sakata k. Acta Oncol. 2002;41(1):63-8. doi: 10.1080/028418602317314082. Acta Oncol. 2002. PMID: 11990521

3

A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma.

Hareyama M, Sakata K, Shirato H, Nishioka T, Nishio M, Suzuki K, Saitoh A, Oouchi A, Fukuda S, Himi T. Hareyama M, et al. Among authors: sakata k. Cancer. 2002 Apr 15;94(8):2217-23. doi: 10.1002/cncr.10473. Cancer. 2002. PMID: 12001120 Free article. Clinical Trial.

4

High-dose-rate intracavitary brachytherapy: results of analyses of late rectal complications.

Sakata K, Nagakura H, Oouchi A, Someya M, Nakata K, Shido M, Koito K, Sagae S, Kudo R, Hareyama M. Sakata K, et al. Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1369-76. doi: 10.1016/s0360-3016(02)03055-9. Int J Radiat Oncol Biol Phys. 2002. PMID: 12459359

5

Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma.

Sakata K, Satoh M, Someya M, Asanuma H, Nagakura H, Oouchi A, Nakata K, Kogawa K, Koito K, Hareyama M, Himi T. Sakata K, et al. Cancer. 2004 Jan 15;100(2):356-65. doi: 10.1002/cncr.11905. Cancer. 2004. PMID: 14716772 Free article.

6

The enhanced expression of the matrix metalloproteinase 9 in nasal NK/T-cell lymphoma.

Sakata K, Someya M, Omatsu M, Asanuma H, Hasegawa T, Ichimiya S, Hareyama M, Himi T. Sakata K, et al. BMC Cancer. 2007 Dec 19;7:229. doi: 10.1186/1471-2407-7-229. BMC Cancer. 2007. PMID: 18093334 Free PMC article.

7

Brachytherapy for oral tongue cancer: an analysis of treatment results with various biological markers.

Sakata K, Someya M, Nagakura H, Nakata K, Oouchi A, Takagi M, Hareyama M. Sakata K, et al. Jpn J Clin Oncol. 2008 Jun;38(6):402-7. doi: 10.1093/jjco/hyn050. Jpn J Clin Oncol. 2008. PMID: 18573850

8

Long survival of patients with unresectable cervical carcinoma after radiotherapy.

Sakata K, Hareyama M, Yama N, Oouchi A, Shido M, Nagakura H, Morita K, Kudo R. Sakata K, et al. Jpn J Clin Oncol. 1997 Aug;27(4):285-7. doi: 10.1093/jjco/27.4.285. Jpn J Clin Oncol. 1997. PMID: 9379521

9

Retrospective DVH analysis of point A based intracavitary brachytherapy for uterine cervical cancer.

Someya M, Hasegawa T, Tsuchiya T, Kitagawa M, Gocho T, Fukushima Y, Hori M, Miura K, Takada Y, Nakata K, Sakata KI. Someya M, et al. Among authors: sakata ki. J Radiat Res. 2020 Mar 23;61(2):265-274. doi: 10.1093/jrr/rrz099. J Radiat Res. 2020. PMID: 32009177 Free PMC article.

10

Evaluation of the urethral α/β ratio and tissue repair half-time for iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy.

Gocho T, Hori M, Fukushima Y, Someya M, Kitagawa M, Hasegawa T, Tsuchiya T, Hareyama M, Takagi M, Hashimoto K, Masumori N, Sakata KI. Gocho T, et al. Among authors: sakata ki. Brachytherapy. 2020 May-Jun;19(3):290-297. doi: 10.1016/j.brachy.2020.02.007. Epub 2020 Apr 2. Brachytherapy. 2020. PMID: 32249179

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,930 results

Search Page